Download Files:
SR-4835
$150 – $780
Products Details
Product Description
– SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1].
Web ID
– HY-130250
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C21H20Cl2N10O
References
– [1]Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424-6.
CAS Number
– 2387704-62-1
Molecular Weight
– 499.36
Compound Purity
– 99.82
SMILES
– CN1N=CC(N2C3=NC(N4CCOCC4)=NC(NCC5=NC6=C(N5)C=C(Cl)C(Cl)=C6)=C3N=C2)=C1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 23 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 1 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Apoptosis;CDK
Isoform
– CDK12;CDK13
Pathway
– Apoptosis;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
